Antonio Maria Grimaldi

4.8k total citations · 1 hit paper
86 papers, 2.3k citations indexed

About

Antonio Maria Grimaldi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Antonio Maria Grimaldi has authored 86 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 40 papers in Molecular Biology and 24 papers in Immunology. Recurrent topics in Antonio Maria Grimaldi's work include Cancer Immunotherapy and Biomarkers (34 papers), Melanoma and MAPK Pathways (33 papers) and CAR-T cell therapy research (26 papers). Antonio Maria Grimaldi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Melanoma and MAPK Pathways (33 papers) and CAR-T cell therapy research (26 papers). Antonio Maria Grimaldi collaborates with scholars based in Italy, United States and Malaysia. Antonio Maria Grimaldi's co-authors include Paolo A. Ascierto, Ester Simeone, Diana Giannarelli, Lucia Festino, Vito Vanella, Corrado Caracò, Nicola Mozzillo, Giuseppe Palmieri, Gabriele Madonna and Mariaelena Capone and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Antonio Maria Grimaldi

85 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

2018 351 citations Mariaelena Capone, Diana Giannarelli et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Antonio Maria Grimaldi

ONCOL

IMMUN

PRM

SURGE

Dominik Rüttinger Germany

Alejandro Martı́n Spain

Sandrine Aspeslagh Belgium

Mariaelena Capone Italy

Katharina C. Kähler Germany

Teresa M. Petrella Canada

Francesco Spagnolo Italy

Rahul Ladwa Australia

Laura Pala Italy

Taher Al‐Tweigeri Saudi Arabia

Dominik Rüttinger Germany

Antonio Maria Grimaldi

1.3k ×0.8

ONCOL

1.3k ×1.7

IMMUN

696 ×1.1

415 ×1.3

PRM

270 ×1.4

SURGE

Citations per year, relative to Antonio Maria Grimaldi Antonio Maria Grimaldi (= 1×) peers Dominik Rüttinger

Countries citing papers authored by Antonio Maria Grimaldi

Since Specialization

Citations

This map shows the geographic impact of Antonio Maria Grimaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Maria Grimaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Maria Grimaldi more than expected).

Fields of papers citing papers by Antonio Maria Grimaldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Maria Grimaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Maria Grimaldi. The network helps show where Antonio Maria Grimaldi may publish in the future.

Co-authorship network of co-authors of Antonio Maria Grimaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Maria Grimaldi. A scholar is included among the top collaborators of Antonio Maria Grimaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Maria Grimaldi. Antonio Maria Grimaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borzillo, Valentina, Rossella Di Franco, Diana Giannarelli, et al.. (2021). Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers. 13(8). 1857–1857. 8 indexed citations

Madonna, Gabriele, Giuseppe Masucci, Mariaelena Capone, et al.. (2021). Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers. 13(16). 4164–4164. 7 indexed citations

Scognamiglio, Giosuè, Mariaelena Capone, Francesco Sabbatino, et al.. (2021). The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers. 13(10). 2325–2325. 9 indexed citations

Ascierto, P.A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2021). LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Annals of Oncology. 32. S1316–S1317. 18 indexed citations

Trolio, Rossella Di, Antonio Maria Grimaldi, Concetta Ingenito, et al.. (2020). Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma. Frontiers in Oncology. 10. 579914–579914. 2 indexed citations

Feo, Gianfranco De, Gerardo Botti, Arturo Capasso, et al.. (2020). Clinical trials and drug cost savings for Italian health service. BMC Health Services Research. 20(1). 1089–1089. 10 indexed citations

Ascierto, Paolo A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2020). LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Annals of Oncology. 31. S1173–S1174. 19 indexed citations

Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2019). Nivolumab for the treatment of small cell lung cancer. Expert Review of Respiratory Medicine. 14(1). 5–13. 6 indexed citations

Capone, Mariaelena, Diana Giannarelli, Domenico Mallardo, et al.. (2018). Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for ImmunoTherapy of Cancer. 6(1). 74–74. 351 indexed citations breakdown →

10.

Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2017). Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. OncoImmunology. 6(3). e1283462–e1283462. 30 indexed citations

11.

Madonna, Gabriele, Carmen Ballesteros‐Merino, Zipei Feng, et al.. (2017). PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology. 7(12). e1405206–e1405206. 46 indexed citations

12.

Vanella, Vito, Lucia Festino, Martina Strudel, et al.. (2017). PD-L1 inhibitors in the pipeline: Promise and progress. OncoImmunology. 7(1). e1365209–e1365209. 36 indexed citations

13.

Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2017). Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs. 31(1). 51–61. 51 indexed citations

14.

Grimaldi, Antonio Maria, et al.. (2017). Cardiac cachexia in sub-Saharan Africa. Indian Heart Journal. 69(6). 784–787. 1 indexed citations

15.

Ascierto, Paolo A., Vito Vanella, Antonio Maria Grimaldi, et al.. (2016). Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunology Immunotherapy. 65(11). 1395–1400. 17 indexed citations

16.

Mozzillo, Nicola, Ester Simeone, Marcello Curvietto, et al.. (2015). Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology. 4(6). e1008842–e1008842. 55 indexed citations

17.

Monta, Gianluca Di, Corrado Caracò, Ugo Marone, et al.. (2015). Clinicopathologic features and surgical management of primary umbilical melanoma: a case series. BMC Research Notes. 8(1). 147–147. 3 indexed citations

18.

Grimaldi, Antonio Maria, Francesco M. Marincola, & Paolo A. Ascierto. (2015). Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy. 16(4). 433–441. 19 indexed citations

19.

Daponte, Antonio, Simona Signoriello, Luigi Maiorino, et al.. (2013). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. Journal of Translational Medicine. 11(1). 38–38. 23 indexed citations

20.

Ascierto, Paolo A., Ester Simeone, Antonio Maria Grimaldi, et al.. (2013). Do BRAF inhibitors select for populations with different disease progression kinetics?. Journal of Translational Medicine. 11(1). 61–61. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact